ARDELYX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 790.00K shares, a 102.05% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 1.10M shares, a 182.05% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 238.00K shares, a 44.13% decline year-over-year.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 861.00K shares, a 29.67% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.88M shares, a 29.16% decline from fiscal 2024.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 2.65M shares, a 1074.34% increase from fiscal 2023.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 226.00K shares, a 1514.29% increase from fiscal 2022.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 14.00K shares, a 95.77% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 790.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.99M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 1.10M shares 10-Q · filed 2026-04-30 | 2.59M shares derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | 238.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | 1.88M shares 10-K · filed 2026-02-19 |
| 2025-09-30 | 861.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | 2.07M shares derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-06-30 | 391.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 1.87M shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 390.00K shares 10-Q · filed 2025-05-01 | 2.34M shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 426.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | 2.65M shares 10-K · filed 2025-02-20 |
| 2024-09-30 | 664.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | 2.33M shares derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-06-30 | 862.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 1.69M shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 702.00K shares 10-Q · filed 2024-05-02 | 892.00K shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 99.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 226.00K shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 28.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | 141.00K shares derived: sum of 4 quarters · filed 2023-10-31 |
| 2023-06-30 | 63.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 113.00K shares derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | 36.00K shares 10-Q · filed 2023-05-03 | 50.00K shares derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-12-31 | 14.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 14.00K shares 10-K · filed 2023-03-02 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 310.00 shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 126.31K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-05 | 320.81K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 310.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 331.31K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 126.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2021-06-30 | 194.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | |
| 2021-03-31 | 10.50K shares 10-Q · filed 2021-05-06 | |
| 2020-12-31 | 445.94K shares 10-K · filed 2021-03-08 | |
| 2020-03-31 | 100.00K shares 10-Q · filed 2021-05-06 | |
| 2019-12-31 | 68.06K shares 10-K · filed 2020-03-06 | |
| 2018-09-30 | 0.00 shares 10-Q · filed 2018-11-07 | |
| 2018-06-30 | 0.00 shares 10-Q · filed 2018-08-07 | |
| 2017-12-31 | 35.76K shares 10-K · filed 2019-03-06 | |
| 2016-12-31 | 25.13K shares 10-K · filed 2019-03-06 | |
| 2015-12-31 | 77.78K shares 10-K · filed 2018-03-14 | |
| 2014-12-31 | 179.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | 336.40K shares 10-K · filed 2017-02-17 |
| 2014-09-30 | 64.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2013-12-31 | 223.87K shares 10-K · filed 2016-03-04 | |
| 2012-12-31 | 342.13K shares 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |